Intratumoral Cancer Therapies Market Summary

• According to DelveInsight’s analysis, the ITCT market size was found to be ~USD 145 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• Intratumoral therapies are reshaping cancer immunotherapy by directly remodeling the tumor microenvironment (TME), achieving high local drug concentrations with reduced systemic toxicity while converting immunologically "cold" tumors into "hot" tumors. This localized immune activation drives both local tumor destruction and systemic antitumor (abscopal) responses, making these therapies highly effective partners for combination regimens, particularly with immune checkpoint inhibitors. 
• Melanoma remains the leading indication, driven by favorable tumor accessibility, strong immunogenicity, and successful integration with checkpoint inhibitors, making it the benchmark for clinical and commercial success. 
• Clinical development is rapidly expanding into pancreatic cancer, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), esophageal cancer, basal cell carcinoma (BCC), adrenocortical carcinoma, soft tissue sarcoma (STS), glioblastoma/brain cancer, prostate cancer, uveal melanoma, gastric cancer, and cutaneous squamous cell carcinoma (cSCC) reflecting growing interest in overcoming resistance in difficult-to-treat solid tumors.
• Regulatory approvals remain limited despite extensive clinical development. To date, only a few intratumoral therapies have achieved commercialization: Talimogene laherparepvec (IMLYGIC) was approved in 2015 (US/EU) for the treatment of unresectable melanoma; Teserpaturev/G47∆ (DELYTACT) received approval in Japan (2021) for malignant glioma; and Telomelysin (OBP-301) was approved in Japan (2026) for locally advanced esophageal cancer.
• Vusolimogene oderparepvec-wtpg (TUDRIQEV, RP1) recently received FDA accelerated approval on August 6, 2026, with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on anti-PD-1 therapy.
• Despite being the first approved intratumoral oncolytic viral therapy, talimogene laherparepvec (IMLYGIC) has achieved limited commercial success due to the absence of a demonstrated overall survival advantage, demanding -70°C cold-chain requirements, and the rapid adoption of more broadly applicable systemic immune checkpoint inhibitors.
• Japan has established itself as the leading launch market for oncolytic virotherapy, with approvals of Teserpaturev (DELYTACT) and Telomelysin supported by flexible regulatory pathways that enable earlier commercialization than the US.
• The emerging intratumoral therapy pipeline is highly diversified, with multiple late-stage and innovative candidates under development by leading companies, including JNJ-1900 (HENSIFY), INT230-6, RP1, NIDLEGY, aglatimagene besadenovec (CAN-2409), MULTIKINE, Ruxotemitide (LTX-315/VP-315), Tigilanol tiglate, LSAM-PTX (NanoPac), LOAd703, BO-112, and Voyager V1 highlighting sustained innovation across viral, immunotherapeutic, gene therapy, nanoparticle, and radioenhancer platforms. 
• Although emerging therapies demonstrate strong early-stage activity, many fail to advance beyond Phase II due to inconsistent efficacy in larger patient populations and operational complexities, resulting in high pipeline attrition.

Intra-tumoral Cancer Therapies (ITCT) Market Size and Forecast in the 7MM

• 2025 Intra-tumoral Cancer Therapies (ITCT) Market Size: ~USD 145 million
• 2036 Projected Intra-tumoral Cancer Therapies (ITCT) Market Size: ~USD XXX million
• Intra-tumoral Cancer Therapies (ITCT) Growth Rate (2026–2036): ~40% CAGR

DelveInsight's ‘Intra-tumoral Cancer Therapies (ITCT) – Market Size, Target Population, Competitive Landscape & Market Forecast – 2036’ report delivers an in-depth understanding of ITCT, historical and forecasted epidemiology, as well as the ITCT market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Intra-tumoral Cancer Therapies (ITCT) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates ITCT patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis. It provides an in-depth market size assessment and growth rate projections (historical & forecast 2022–2036) across global regions. The report highlights key unmet medical needs in ITCT and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Intra-tumoral Cancer Therapies (ITCT) Market

• Increasing cancer cases and growing treatment burden

The rising global incidence of cancer, particularly advanced and difficult-to-treat solid tumors, is increasing the demand for innovative treatment approaches and expanding the potential patient pool for ITCTs.

• Advances in immuno-oncology and combination therapies 

Rapid advances in cancer immunotherapy, including immune checkpoint inhibitors, oncolytic viruses, cancer vaccines, and immune agonists, are expanding the ITCT pipeline. Combining intratumoral therapies with established systemic treatments may further enhance antitumor immune responses and broaden their clinical applications.

• Growing preference for localized and minimally invasive therapies 

The ability to deliver therapies directly into tumors can achieve high local drug concentrations while potentially reducing systemic exposure and associated toxicities, increasing interest in intratumoral treatment approaches.

Intra-tumoral Cancer Therapies (ITCT) Understanding Algorithm

Intra-tumoral Cancer Therapies (ITCT)  Overview and Diagnosis

Cancer is a diverse disease, as the signs, symptoms, and treatment vary among the various cancer types, making it essential to develop a specified therapy for the patients. Currently available cancer treatment options include immunotherapy, radiotherapy, chemotherapy, targeted drug therapy, and others. Although these therapies have improved the OS and outcomes of patients, they possess some limitations and cannot benefit all patients. Scientists are focused on developing treatment options that can overcome these challenges, and one such emerging treatment option is intra-tumoral cancer therapies.

Intra-tumoral immunotherapy is a revolutionary cancer treatment that uses sophisticated antibodies directly injected into the cancer tumors instead of through a vein (intravenously). These therapies aim to deliver immunostimulatory products directly into a tumor lesion (primary or metastatic) to prime and/or boost an antitumor immune response.

Further details related to country-based variations are provided in the report.

Intra-tumoral Cancer Therapies (ITCT) Unmet Needs

The section “unmet needs of ITCT” outlines critical gaps between the current state of patient care and diagnosis and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress. 

1. Lack of standardization in dosing, technique, and response assessment
2. Limited systemic (abscopal) response in metastatic disease 
3. Limited late-stage clinical evidence and Phase III setbacks
4. Limited number of approvals, and others…..

Note: Comprehensive unmet needs insights in ITCT and their strategic implications are provided in the full report.

Intra-tumoral Cancer Therapies (ITCT) Epidemiology

Key Findings from Intra-tumoral Cancer Therapies (ITCT) Epidemiological Analysis and Forecast

The intra-tumoral cancer therapies epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total cases of selected indications in the 7MM, Indication wise target patient pool of Intra-tumoral Cancer Therapies in the 7MM, and Indication wise treated cases of Intra-tumoral Cancer Therapies in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2022 to 2036.

• In 2025, the total cases of selected indications for ITCT were 11.2 million cases in the 7MM, which is anticipated to increase by 2036. Among all the indications, BCC accounted for the highest number of cases, i.e., 5 million cases in 2025, which are expected to increase by 2036 during the forecast period (2025–2036). 
• In the United States, the total indication-wise treated cases for ITCT accounted for 3.6 million cases in 2025 and are expected to increase by 2036.
• NSCLC had the second-highest number of incidence cases amongst the 7MM. Uveal melanoma and adrenocortical carcinoma were the cancers with the least number of cases.

Intra-tumoral Cancer Therapies (ITCT) Drug Analysis & Competitive Landscape

The ITCT drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I–III clinical trials. It covers the mechanism of action, clinical trial data, patents, collaborations, and strategic partnerships, key upcoming catalysts for each therapy, and their advantages, limitations, and recent developments. This section offers critical insights into the ITCT treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the ITCT therapeutics market.

Approved Therapies for Intra-tumoral Cancer Therapies (ITCT)

Talimogene laherparepvec (IMLYGIC): Amgen

Talimogene laherparepvec is a genetically modified herpes simplex virus type-1 (HSV-1) designed to replicate within tumors and produce an immunostimulatory protein called GM-CSF. Talimogene laherparepvec causes cell lysis, or death, which ruptures tumors, releasing tumor-derived antigens, which, along with GM-CSF, may promote an anti-tumor immune response. However, the exact mechanism of action is unknown.

Teserpaturev/G47∆ (DELYTACT): Daiichi Sankyo 

Teserpaturev, jointly developed by Daiichi Sankyo and the University of Tokyo’s Institute of Medical Science, is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1). DELYTACT has triple mutations within the viral genome that cause augmented and selective replication in cancer cells and enhanced induction of antitumor immune response while retaining high safety features. DELYTACT is currently the first third-generation oncolytic HSV-1 to be evaluated in humans. 

Note: Detailed list will be provided in the final report.

Emerging Therapies for Intra-tumoral Cancer Therapies (ITCT)

INT230-6: Intensity Therapeutics

INT230-6 is a formulation consisting of a proprietary amphiphilic cell penetration enhancer molecule, 8-(2-hydroxybenzoyl amino octanoate), also referred to as SHAO, and combined with cisplatin and vinblastine. The penetration enhancer facilitates the dispersion of the two drugs throughout injected tumors and enables increased diffusion into cancer cells. Nonclinical safety studies showed no evidence of the drug penetrating healthy tissue. INT230-6 is currently being studied in multiple Phase II clinical cohorts to treat several types of metastatic cancers in the US and Canada. 

INT230-6 received FDA Fast Track designation for relapsed/metastatic TNBC in 2019 and ODD for STS in 2023.

Aglatimagene besadenovec (CAN-2409): Candel Therapeutics

Aglatimagene besadenovec is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the HSV thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. Together, this regimen is designed to induce an individualized and specific CD8+ T-cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity based on in situ vaccination against a variety of tumor antigens. Because of its versatility, aglatimagene besadenovec has the potential to treat a broad range of solid tumors. 

Aglatimagene besadenovec received FDA FTD for NSCLC (2023) and PDAC (2023), ODD for pancreatic cancer (2024), and RMAT Designation for localized intermediate- to high-risk prostate cancer (2025); Candel also collaborated with IDEA Pharma for commercial strategy in March 2025.

Note: Detailed emerging therapies assessment will be provided in the final report.

Note: Detailed list will be provided in the final report.

Intra-tumoral Cancer Therapies (ITCT)  Key Players, Market Leaders and Emerging Companies

• Amgen
• Daiichi Sankyo
• Oncolys BioPharma
• NANOBIOTIX
• Johnson & Johnson 
• Intensity Therapeutics, 
• Replimune 
• Candel Therapeutics 
• CEL-SCI 
• Cytovation ASA 
• Medicenna Therapeutics, and others

Intra-tumoral Cancer Therapies (ITCT) Drug Updates

• In August 6, 2026, the FDA granted accelerated approval to vusolimogene oderparepvec-wtpg (TUDRIQEV, Replimune), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. 
• In July 2026, CEL-SCI announced it is launching its global Confirmatory Registration Study of MULTIKINE (Leukocyte Interleukin, Injection) as a neoadjuvant treatment for newly diagnosed, previously untreated, resectable, locally advanced primary HNC.
• In July 2026, Intensity Therapeutics provided a mid-year update highlighting the Company's late-stage development programs and growing strategic partnering focus for INT230-6. 
• In June 2026, during fiscal fourth quarter financial results, Replimune anticipated the Phase II/III (REVEAL study) transition in Q1 2027 for RP2 therapy.
• In May 2026, a 3-year landmark overall survival analysis from the IGNYTE clinical trial of vusolimogene oderparepvec was recently presented at the 2026 ASCO annual meeting. 
• In April 2026, Candel Therapeutics announced it will resume enrollment of the INVINCIBLE-3 study in a limited number of US sites by Q3 2026.
• In March 2026, Candel Therapeutics is in an ongoing dialogue with the FDA in preparation for the anticipated submission of a BLA for aglatimagene besadenovec in prostate cancer in Q4 2026.

Intra-tumoral Cancer Therapies (ITCT) Market Outlook

Cancer has been a focal point for research and development, and with time, the treatment paradigm has improved significantly. Cancer treatment mainly comprises surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy, immunotherapy, and stem cell transplantation. However, despite several treatment options, death rates are relatively high as these therapies have limitations and cannot target every patient. Few cancer therapies face the challenge of accessing targets deep within tumor tissue; some cause serious AEs.  Cancer patients have multiple treatment-related unmet needs, so researchers are working on developing intra-tumoral therapies. Intra-tumoral (intralesional) immunotherapeutic delivery is a compelling solution to address local impediments to tumor immunity. Even though intra-tumoral therapy most factually means injecting directly into tumors, it can refer to any therapy delivered in close anatomical proximity with the intention of direct uptake by tumor cells

The field has gained important regulatory validation with talimogene laherparepvec (IMLYGIC), nadofaragene firadenovec (HENSIFY), teserpaturev (DELYTACT), and most recently RP1 (Tudriqev). On August 6, 2026, the FDA granted accelerated approval to RP1 in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed following anti-PD-1 therapy, strengthening the clinical position of next-generation oncolytic immunotherapies. 

The pipeline continues to expand across melanoma, HNSCC, STS, NSCLC, and BCC, with candidates such as NIDLEGY, INT230-6, AdAPT-001, aglatimagene besadenovec, and BO-112 employing diverse mechanisms. Future growth is expected to be driven by biomarker-based patient selection and combinations with checkpoint inhibitors, radiotherapy, and other systemic therapies, potentially shifting intratumoral therapy from a niche approach toward a broader component of precision oncology. 

Overall, the emergence of first-in-class intratumoral therapies, expanding clinical adoption, and growing awareness of localized immunotherapy approaches are expected to drive steady growth in the 7MM ITCT market from 2022–2036, with strong commercial potential across marketed therapies and emerging pipelines.

• The therapeutic market size of intra-tumoral cancer therapies in the 7MM was approximately USD 145 million in 2025.
• The market size in the 7MM will increase at a CAGR of 40% due to increasing awareness of the disease, better diagnosis, and the launch of emerging therapies.
• The United States accounted for the highest market size of intra-tumoral cancer therapies, approximately 65% (~USD 90 million) of the total market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• With the expected launch of upcoming therapies, such as SP-002 (ASN-002) and Bizaxofusp (MDNA55), the total market size of intra-tumoral cancer therapies is expected to show change in the upcoming years.

Further details will be provided in the report….

Drug Class/Insights into Leading Emerging and Marketed Therapies in Intra-tumoral Cancer Therapies (ITCT) (2022-2036)

The ITCT pipeline includes therapies designed to modify the tumor microenvironment directly, induce tumor-cell death, stimulate systemic antitumor immunity, and enhance responses to immune checkpoint inhibitors. Emerging modalities include oncolytic viruses, intratumoral immunomodulators, gene therapies, cancer vaccines, and cytokine-based approaches, with the broader goal of achieving localized tumor control while generating systemic immune responses and overcoming resistance to conventional and immuno-oncology therapies.

• Intratumoral gene therapies: Deliver genetic material directly into tumors to induce antitumor immune responses or modify tumor biology. Nadofaragene firadenovec (HENSIFY) is an intravesical adenoviral gene therapy delivering interferon alfa-2b for bladder cancer. At the same time, RP1 (Tudriqev) is an emerging selectively replicating HSV-1-based immunotherapy designed to enhance tumor-cell killing and systemic immunity. 
• Intratumoral immune agonists: Activate innate or adaptive immune pathways within the tumor microenvironment to promote immune-cell recruitment and tumor destruction. Agents targeting Toll-like receptors (TLRs), STING, and other innate immune pathways are being investigated, often in combination with immune checkpoint inhibitors. 
• Intratumoral cancer vaccines: Deliver tumor-associated antigens directly into or around tumors to stimulate tumor-specific T-cell responses and potentially generate systemic immunity. These approaches are being explored as monotherapy and in combination with checkpoint inhibitors.

Intra-tumoral Cancer Therapies (ITCT) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026–2036). The analysis covers the ITCTdrug’s uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug. The uptake of emerging ITCT therapies is expected to vary based on clinical efficacy, durability of response, safety, tumor type, administration route, combination potential, physician familiarity, and reimbursement. CY-101, JNJ-1900 (HENSIFY/NBTXR3), and BO-112 may achieve relatively faster or moderate adoption as clinical evidence matures, particularly where combination with checkpoint inhibitors demonstrates meaningful benefit. SP-002 (ASN-002), INT230-6, Hiltonol (Poly ICLC), Voyager V1, and VG161 are expected to see gradual uptake as efficacy, durability, safety, and long-term outcomes become established. Talimogene laherparepvec (IMLYGIC) and Teserpaturev (DELYTACT) may maintain adoption in their respective indications, although newer intratumoral approaches could influence future utilization.

Overall, adoption is expected to build gradually, with broader uptake driven by durable tumor responses, systemic immune activation, favorable safety, compatibility with checkpoint inhibitors, ease of administration, and supportive reimbursement.

Further detailed analysis of emerging therapies' drug uptake in the report…

Market Access and Reimbursement of Approved Therapies in Intra-tumoral Cancer Therapies (ITCT)

The report also provides detailed insights on country-wise accessibility and reimbursement scenarios, cost-effectiveness scenarios for approved therapies, programs that make access easier and out-of-pocket costs more affordable, and insights on patients insured under federal or state government prescription drug programs.

• The United States

Reimbursement is a crucial factor that affects the drug’s access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders. 

NOTE: Further Details are provided in the final report….

Intra-tumoral Cancer Therapies (ITCT) Therapies Price Scenario & Trends 

Pricing and analogue assessment of ITCT therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of ITCT Approved Drugs

Amgen launched Talimogene Laherparepvec in the US with a Wholesale Acquisition Cost (WAC) of USD 4,400 for a 100 million PFU/mL single-use vial, resulting in an annual treatment cost of approximately USD 65,000 in 2015.

Industry Experts and Physician Views for Intra-tumoral Cancer Therapies (ITCT)

To keep up with ITCT market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on ITCT emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in ITCT, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the National Institutes of Health, Heidelberg University Hospital, The Institute of Cancer Research, University of Milan, etc., were contacted. Their opinion helps understand and validate current and emerging ITCT therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in ITCT.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. 

In the SWOT analysis of Intra-tumoral Cancer Therapies (ITCT), strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. For efficacy, the trial’s primary and secondary outcome measures are evaluated, whereas the therapies’ safety is evaluated, wherein acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of intra-tumoral cancer therapies, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the intra-tumoral cancer therapies market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM intra-tumoral cancer therapies market.

Report Insights

• Intra-tumoral Cancer Therapies (ITCT) Patient Population Forecast
• Intra-tumoral Cancer Therapies (ITCT) Therapeutics Market Size 
• Intra-tumoral Cancer Therapies (ITCT) Pipeline Analysis
• Intra-tumoral Cancer Therapies (ITCT) Market Size and Trends
• Intra-tumoral Cancer Therapies (ITCT)  Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report 
• 11-Year Forecast 
• Intra-tumoral Cancer Therapies (ITCT) Market Outlook (North America, Europe, Asia-Pacific) 
• Patient Burden Trends (By Geography)
• Intra-tumoral Cancer Therapies (ITCT) Treatment Addressable Market (TAM)
• Intra-tumoral Cancer Therapies (ITCT) Competitive Landscape
• Intra-tumoral Cancer Therapies (ITCT) Major Companies Insights
• Intra-tumoral Cancer Therapies (ITCT) Price Trends and Analogue Assessment
• Intra-tumoral Cancer Therapies (ITCT) Therapies Drug Adoption/Uptake
• Intra-tumoral Cancer Therapies (ITCT) Therapies Peak Patient Share Analysis

Report Assessment

• Intra-tumoral Cancer Therapies (ITCT) Current Treatment Practices
• Intra-tumoral Cancer Therapies (ITCT) Unmet Needs
• Intra-tumoral Cancer Therapies (ITCT) Clinical Development Analysis
• Intra-tumoral Cancer Therapies (ITCT) Emerging Drugs Product Profiles
• Intra-tumoral Cancer Therapies (ITCT) Market Attractiveness
• Intra-tumoral Cancer Therapies (ITCT) Qualitative Analysis (SWOT and Conjoint analysis)

FAQs

• What is the historical and forecasted Intra-tumoral Cancer Therapies patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What was the Intra-tumoral Cancer Therapies total market size, the market size by therapy, and the market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• Which therapy is going to be the largest contributor by 2036?
• What are the pricing variations among different geographies for approved and off-label therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? 

Reasons to Buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Intra-tumoral Cancer Therapies Market.
• Insights on patient burden/disease cases, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.